Capstone Therapeutics Corporation has announced a significant financial agreement involving the issuance of senior secured convertible notes to an institutional investor. The total principal amount of these notes is set at $10,909,885, with an 8.34% original issue discount. Initially, a Convertible Note worth approximately $3,272,966 was issued, convertible into shares of Capstone's common stock at a conversion price of $1.72 per share. However, as of August 15, 2025, the company and the investor mutually agreed to adjust the conversion price to $1.00 per share. This adjustment allows conversion up to a principal amount of $1,363,736 under the new terms. This strategic move is expected to enhance the investor's ability to convert the notes and potentially increase the liquidity of Capstone's common stock.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。